Evidence-based treatment of atopic eczema in general practice by Khumalo, NP
The prevalence of atopic eczema (AE) in
Western societies is estimated at 10 - 20%
in children under 14 years of age. South
African rural, peri-urban and urban fig-
ures are 0.7%, 1.1% and 3.7%, respec-
tively (Professor G Todd — personal com-
munication). Although there may be indi-
vidual variations, patients with AE gener-
ally have a higher incidence of asthma and
hay fever, as well as a history of similarly
affected family members. The exact cause
is unknown but a combination of genetic
and environmental factors probably inter-
acts. The importance of environmental
factors is emphasised by the observation
of a higher incidence of AE in relatives
who have moved from rural to more
urban communities.
CLINICAL FEATURES
Acute eczema is characterised by red,
itchy skin and often by vesicles that ooze
serum, resulting in crust formation.
Scratching may result in secondary infec-
tion and associated complications.
In chronic eczema recurrent scratching
results in thickening of the skin, promi-
nence of skin marking and colour change
(hyperpigmentation or hypopigmenta-
tion); this combination of signs is some-
times referred to as lichenification.
The clinical presentation of AE differs
somewhat according to the age of the
patient.
Infantile AE
The onset may be as early as within the
first few weeks of life.There is a predilec-
tion for involvement of the head and neck,
especially the face (Fig. 1). Distinction
from infantile seborrhoeic dermatitis may
be difficult, but the latter is characterised
by the presence of a greasy scale (so-
called ‘cradle cap’) and the absence of
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of AE differs somewhat
according to the age of
the patient. Fig. 1. Child with moderately severe atopic
eczema.
itch, which may be difficult to
assess in the very young.
Childhood AE
After the age of 2 years the skin
lesions tend to have a predilection
for the folds, especially the antecu-
bital and popliteal fossae of the
arms and legs, respectively (Fig. 2).
Adult AE
In the older patient skin involve-
ment may be similar to childhood
eczema or localised to one area,
e.g. hand dermatitis.
In more severe disease, involve-
ment in all age groups may be
more extensive and in some cases
may encompass more than 90% of
the integument (if acute and red,




There are many remedies in use,
and consequently many claims of
usefulness are made by both
patients and doctors. This article
only looks at evidence from dou-
ble-blind, randomised controlled
trials (RCTs), which are largely
regarded as the best evidence for
the effectiveness of interventions.
UP TO THE YEAR 2000
RCTs of interventions for AE are
comprehensively summarised in a
systematic review by Hoare and
co-workers.1 This review is exten-
sive and summarises data from 272
RCTs covering 47 different inter-
ventions. The authors state that
‘there was reasonable RCT evi-
dence to support the use of oral
cyclosporin, topical corticosteroids,
psychological approaches and UV
therapy’ (as quoted by Bigby). 2
There was either insufficient or no
RCT evidence for many other
interventions, such as maternal
allergy avoidance for disease pre-
vention, oral antihistamines,
evening primrose oil, emollients,
avoidance of enzymatic washing
powders, cotton as opposed to syn-
thetic fibres for clothing, and the
use of twice-daily as opposed to
once-daily topical corticosteroids.
It is important, however, always to
remember that the absence of evi-
dence does not necessarily mean
that the intervention is not success-
ful.
An RCT which we think may be of
particular value for general practi-
tioners, is one which examined the
effect of antihistamines in relieving
pruritus. This study3 concluded the
following:‘Although antihistamines
are often used in the treatment of
atopic dermatitis, little objective
evidence exists to demonstrate
relief of pruritus. The majority of
trials are flawed in terms of the
sample size or study design. Based
on the literature alone, the efficacy
of antihistamines remains to be
adequately investigated.
Anecdotally, sedating antihista-
mines have sometimes been useful
by virtue of their soporific effect
and bedtime use may be warrant-
ed.There is no evidence to support
the effectiveness of expensive non-
sedating agents.’
AFTER THE YEAR 2000
The following abstracts of a num-
ber of RCTs published after the
abovementioned review1 may be
useful to the general practitioner:
• ‘Moisturizers are widely used in
AE.The use of 20% glycerin
cream was compared with the
urea-saline cream. No differ-
ences were found regarding skin
reactions such as stinging, itch-
ing and dryness/irritation.’ The
study concluded that a ‘glycerin
containing cream appears to be
a suitable alternative to
urea/sodium chloride in the
treatment of atopic dry skin’.4
• Short bursts of a potent corti-
costeroid (0.1% betamethasone
valerate applied for 3 days fol-
lowed by the base ointment for
4 days) were compared with a
mild steroid (1% hydrocortisone
applied for 7 days) in mild or
moderate AE in patients recruit-
ed from general practices and
from a hospital outpatient clinic.
The study5 concluded that: ‘A
short burst of a potent topical
corticosteroid is just as effective
as prolonged use of a milder
preparation for controlling mild
or moderate AE in children.’
The study duration was 18
weeks.
• House dust mite allergy is com-
mon in AE and, although closely
associated with hay fever (aller-
gic rhinitis), it has also been sus-
pected of increasing the severity
of AE. Oosting et al.6 investigat-
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ed this association and conclud-
ed that: ‘Use of house dust
mite-impermeable encasings
resulted in a significant decrease
in allergen concentrations.
However, this reduction in aller-
gen load did not result in signifi-
cant changes in clinical parame-
ters between the groups.’
• The wet-wrap dressing tech-
nique has proved to be benefi-
cial in cases of exacerbated
atopic dermatitis (AD) skin
lesions.The aim was to investi-
gate the effect of wet-wrap
dressings in a controlled trial
comparing a steroid-containing
(mometasone furoate 0.1%) and
a steroid-free (vehicle) prepara-
tion in an inpatient comparison
study.Twenty children aged 2 -
17 years with exacerbated AD
were treated twice daily with
wet-wrap dressings over a 5-day
period. The study concluded
that ‘Application of the wet-
wrap dressing technique for
exacerbated AD lesions is effec-
tive, combination with a topical
steroid being superior to a
steroid-free application without
bearing the risk of a bacterial
superinfection.’7
• A systematic review of the bene-
fit of breast-feeding in prevent-
ing AE concluded that:
'Exclusive breast-feeding during
the first 3 months of life is asso-
ciated with lower incidence rates
of AD during childhood in chil-
dren with a family history of
atopy. This effect is lessened in
the general population and neg-
ligible in children without first-
order atopic relatives. Breast-
feeding should be strongly rec-
ommended to mothers of
infants with a family history of
atopy, as a possible means of
preventing AE.’8
• The effect of early supplementa-
tion with gamma-linoleic acid
(GLA)  (i.e. oil of evening prim-
rose) given as borage oil supple-
ment (containing 100 mg GLA)
or sunflower oil supplement as a
placebo daily for the first 6
months of life was investigated
by Van Gool and co-authors.9
The main outcome measures
were the following: the inci-
dence of AD in the first year of
life (by UK Working Party crite-
ria), the severity of AD
(SCORing Atopic Dermatitis;
SCORAD), and the total serum
immunoglobulin E (IgE) con-
centration at the age of 1 year.
The results showed a favourable
trend for severity of AD associ-
ated with GLA supplementation
(SCORAD ± SD: 6.32 ± 5.32)
in the GLA-supplemented
group compared with 8.28 ±
6.54 in the placebo group (p =
0.09; p = 0.06 after adjustment
for total serum IgE at baseline,
age 1 week). However, there
were no significant effects on
the other atopic outcomes.The
authors’ conclusion was that
‘Early supplementation with
gamma linoleic acid in children
at high familial risk does not
prevent the expression of atopy
as reflected by total serum IgE,
but it tends to alleviate the
severity of atopic dermatitis in
later infancy in these children.’
• Two recent RCTs examined the
effectiveness of tacrolimus (a
synthetic immune modulator
with cyclosporin-like effects) in
AE.The study by Reitamo and
co-workers10 concluded that:
‘The efficacy of 0.1% tacrolimus
ointment was similar to that of
0.1% hydrocortisone butyrate
ointment and was lower for
0.03% tacrolimus ointment. No
serious safety concerns were
identified.’ (Please note that
0.1% hydrocortisone butyrate
ointment is a potent corticos-
teroid with similar strength to
betamethasone valerate.) In
another study11 the same group
compared tacrolimus to 1%
hydrocortisone acetate (a mild
corticosteroid) and concluded
that: ‘Tacrolimus, 0.03% and
0.1%, was significantly more
effective than 1% hydrocorti-
sone acetate and 0.1%
tacrolimus was more effective
than 0.03% tacrolimus in the
treatment of moderate-to-severe
AD in children. No safety con-
cerns were identified.’
• A recent study12 on the effective-
ness of pimecrolimus compared
with placebo showed impressive
results: ‘First flare was 144 days
in the pimecrolimus group and
26 days in the control group 
(p < 0.001). Pimecrolimus treat-
ment was also associated with
improvement in signs and symp-
toms of AD, pruritus, patients'
self-assessment and quality of
life.’ The authors concluded
that: ‘Pimecrolimus cream 1%
bid is an effective, well-tolerat-
ed, long-term treatment for AD
in adults, substantially reducing
the number of flares compared
to a conventional therapy and
consequently reducing or elimi-
nating the need for corticos-
teroid.’
• Azathioprine has been used
anecdotally and has now been
proved in an RCT to be ‘an
effective and useful drug in
severe AD although it is not
always well-tolerated.
Monitoring of the full blood
count and liver enzymes is
advisable during treatment.’13
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SUGGESTED PRACTICAL
MANAGEMENT OF AE
• Diagnosis. Making the correct
diagnosis is largely dependent on
the history (personal and family
history of atopy, i.e. asthma, hay
fever) and examination (acute ver-
sus chronic eczema and areas of
predilection).
• Moisturisers. Although there are
no RCTs on the effect of soap, we
have found the substitution of soap
with aqueous cream very helpful
(less drying and therefore less like-
ly to induce itch and scratching).
We recommend petroleum jelly or
emulsifying base as a moisturi s e r.
These are oily and may not be
acceptable to all patients, in which
case water-based moisturisers such
as aqueous, cetomacrogol, liquid
paraffin and other creams contain-
ing glycerin or urea 4 may be more
acceptable. Generally, lotions are
not very useful. To reduce the risk
of added irritants we warn our
patients to avoid antiseptic, topical
antihistamine and perfume-con-
taining creams and ointments.
• Topical steroids. For acute
flares, we recommend the use of
1% hydrocortisone acetate to the
face and neck and topical
betamethasone to the body as well
as wet wraps7 (we use two layers of
cotton tubular bandage as a dress-
ing, a wet (damp — warm water)
layer underneath and a dry layer
on top) for up to a maximum of 5
days (see Figs 3 and 4). It is
important to continue with the 
liberal use of moisturiser. The use
of wet wraps may be continued
even without topical corticos-
teroids (i.e. with moisturiser
alone).The advantages of wet
wraps include increased contact
with the skin during treatment
(topical steroid is not rubbed off
onto bed linen), and reduction of
the skin temperature — thus
reducing warmth, sweating and
itch and indirectly improving sleep.
The quantity of topical steroid is
measured according to the ‘finger
tip’ method.14
• Antihistamines. The effect of
antihistamines on itch has not been
proved beyond doubt, but sedating
antihistamines are useful by virtue
of their soporific effect.There is no
evidence to support the effective-
ness of expensive non-sedating
agents.
• Oil of evening primrose may
be helpful, but more RCTs are
needed to confirm the beneficial
effects, particularly in view of the
cost involved.Therefore oil of
evening primrose is not routinely
recommended in our centre but
neither is it discouraged in the
individual patient who inquires
about its usefulness (discuss the
insufficient evidence with the
patient or parent).
• Newer macrolide treatments.
There is an excellent chapter by
Williams et al.15 on the evidence-
based treatment of AE. It sum-
marises data from 7 RCTs on tra-
colimus as follows:‘About a third
of study participants with moder-
ate-to-severe AE achieve excellent
results, defined as at least 90%
improvement in the physician’s
global assessment. A transient
burning sensation is a common
side-effect that occurs in about half
of adults investigated, but is sel-
dom severe enough to necessitate
stopping treatment.’
Tacrolimus is recommended for
moderate to severe disease, where-
as pimecrolimus is effective in mild
to moderate disease. In the USA,
pimecrolimus is approved for
‘short-term intermittent therapy in
the treatment of mild-to-moderate
AD in non-immunocompromised
patients 2 years or older, in whom
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Fig. 3. Wet-wrap treatment of a baby.
Fig. 4. Wet wraps in an older child.
Note relative sparing of the face.
the use of alternative, conventional
therapies is deemed inadvisable . . .
or in patients who are not ade-
quately responsive or are intolerant
to conventional therapies.’16
Note that the effect of these treat-
ments is equivalent to moderately
potent topical steroids. Topical
steroids are safe and effective, pro-
vided they are used for short, inter-
mittent periods as recommended
above.The use of the newer bio-
logical treatments is limited by the
cost and availability.
What about patients who do not
respond? They should be referred
to a dermatologist for considera-
tion of other treatment which may
include ultraviolet light (with or
without topical or oral psoralens),
azathioprine, and cyclosporin. Oral
steroids are best avoided for the
treatment of AE.
We wish to thank Dr S Jessop for her
helpful comments on the manuscript.
References
1. Hoare C, et al. Health Technol Assess 2000;
4: 1-191.
2. Bigby M. Arch Dermatol 2001; 137: 1635-
1636.
3. Klein PA, et al. Arch Dermatol 1999; 135:
1522-1525.
4. Loden M, et al. Acta Derm Venereol 2002;
82: 45-47.
5. Thomas KS, et al. BMJ 2002; 324: 768.
6. Oosting AJ, et al. J Allergy Clin Immunol
2002; 110: 500-506.
7. Schnopp C, et al. Dermatology 2002; 204:
56-59.
8. Gdalevich M, et al. J Am Acad Dermatol
2001; 45: 520-527.
9. Van Gool CJ, et al. Am J Clin Nutr 2003;
77: 943-951.
10. Reitamo S, et al. J Allergy Clin Immunol
2002; 109: 547-555.
11. Reitamo S, et al. J Allergy Clin Immunol
2002; 109: 539-546.
12. Meurer M, et al. Dermatology 2002; 205:
271-277.
13. Berth-Jones J, et al.Br J Dermatol 2002;
147: 324-330.
14.  Long C, et al. Clin Exp Dermatol 1991; 
16: 444-447.
15.  Williams H, et al. Evidence-based
Dermatology. London: BMJ Books, 2003:
144-225.




534 C M E S e p t e m b e r  2 0 0 3   Vo l . 2 1   N o . 9
IN A NUTSHELL
Atopic eczema (AE) is a common
chronic condition characterised by a
dry, itchy skin, associated with flares
and remissions.
The exact cause of AE is unkown,
but a combination of genetic and
environmental factors probably inter-
acts. The importance of the latter is
emphasised by the observation of an
increased incidence in relatives who
have moved from a rural to an urban
environment.
The clinical presentation varies
according to the age of the patient.
Many remedies are usually tried by
both the patient and the doctor, but
we only consider treatments based
on evidence from randomised con-
trolled trials (RCTs).
Practical management consists of the
correct diagnosis, moisturising the
skin with aqueous cream or petrole-
um jelly, topical steroids and wet
wraps in acute flare-ups, and the use
of the newer macrolide treatments in
patients with moderate to severe AE.
However, use of the latter is limited
by cost and availability.
Breast-feeding by a mother with a
history of atopy may go some way
towards preventing a child from
developing eczema later in life.
The usefulness of antihis tamines to
prevent itch has not been proved
beyond doubt, nor has that of
evening primrose oil.
SINGLE SUTURE
Using household possessions to identify the poor
Information on income and expenditure are difficult and time-consuming to obtain, but those working on
child-health interventions need information on household economic status. An alternative is to use informa-
tion on household possessions and characteristics of a family’s house. For example, households owning a car
can be judged to be wealthier than those owing a motorcycle, which in turn are deemed wealthier than those
owning only a bicycle. Electricty implies wealth, as does ownership of a television rather than just a radio.
Such information, which is available in demographic, health and other surveys, can be combined into one
index of wealth by various means.
(Victoria CG, et al.Lancet 2003; 362: 233-241.)  
